Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 22, 2024 1:14pm

63 Views

Post# 36101652

RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

May 14, 2024 - Recent Trends in the Global Cancer Biologics Market

In recent years, the global cancer biologics market has witnessed several notable trends that have reshaped its dynamics:

Rise of Targeted Therapies: Targeted therapies have emerged as a significant driver of demand in the global cancer biologics market. These therapies, designed to specifically interfere with the molecular and genetic pathways driving cancer growth, have revolutionized oncology treatment by offering enhanced efficacy and reduced side effects.
Precision Medicine Revolution: Targeted therapies are at the forefront of the precision medicine revolution in oncology. Through the identification of specific genetic mutations and biomarkers, oncologists can tailor treatment regimens to individual patients, leading to more effective outcomes.
Advancements in Oncolytic Viruses and NGS Technologies: Oncolytic viruses and next-generation sequencing (NGS) technologies have deepened our understanding of the genetic underpinnings of cancer. This has paved the way for personalized medicine strategies, wherein treatments are customized based on the unique genetic profiles of patients.
Liquid Biopsies: Liquid biopsies have emerged as a less intrusive alternative to conventional tissue biopsies. These tests enable the monitoring of treatment efficacy, identification of minimal residual disease, and pinpointing of mechanisms of resistance, thereby facilitating more informed treatment decisions.